

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

<https://marketpublishers.com/r/PD05B68E42AEN.html>

Date: August 2012

Pages: 220

Price: US\$ 2,500.00 (Single User License)

ID: PD05B68E42AEN

Abstracts

What Will the Pharma Industry Look Like in 5 Years?

There are an estimated 724 projects in development from the top 50 pharmaceutical companies. Together, they have the potential to add billions in value to the current pharmaceutical market in the next five years. What types of drugs are companies developing and what will be the impact of these products on the marketplace and key competitors? In this report, Kalorama Information has analyzed the late-stage R&D pipeline of the 50 top companies in pharmaceuticals - the companies that produce the lion's share of industry revenues.

Coverage of the 50 Leading Companies

This report takes a look at the pipeline of the following companies. The top companies include pharmaceutical companies that are considered to be the top 50 companies worldwide in terms of generated revenues, these include:

Abbott Laboratories

Actelion

Allergan

Amgen

Astellas

AstraZeneca

Baxter International

Bayer

Biogen IDEC

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene Corp.

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly & Co.

Forest

Gilead Sciences

GlaxoSmithKline

Grifols SA

Hospira

Johnson & Johnson

Kyowa Kirin

Lundbeck

Menarini

Merck

Merck KGaA

Mitsubishi Tanabe Pharma

Mylan

Novartis

Novo Nordisk

Ono Pharmaceutical Co.

Otsuka Pharmaceutical

Pfizer

Purdue Pharma

Reckitt Benckiser

Roche

Sanofi

Santen Pharmaceuticals

Servier

Shionogi

Shire

Taisho Pharmacueitcal

Takeda

TEVA

UCB

Valeant Pharmaceuticals

Warner Chilcott

Watson

While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Pipeline Analysis, Key Trends, Market Forecasts

This Kalorama Information market research report captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines and OTC products) and providing estimates and forecasts of the world biopharma market.

As part of its coverage, the report provides the following:

Company Analysis

Pipeline Snapshot: Top 20 Companies

Market Trends and Value

Evaluating Changes in 2011 Market Value

The Traditional Pharmaceutical Market

Biotechnology Market Facts and Forecast

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical and biopharmaceutical products; consumer pharmaceuticals and products; diagnostics; devices; chemicals; agriculture; and animal health. These are areas where many of these companies also compete with significant market shares.

Contents

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction
Scope and Methodology
Potential Market Opportunity
Issues and Trends Affecting Market
Leading Companies

CHAPTER TWO: INTRODUCTION

Global Pharmaceutical Market
Pharmaceutical Research & Development Overview
Expanded Options in Treating Diseases

CHAPTER THREE: ISSUES AND TRENDS

Biotechnology Drug Development
Orphan Drugs
Fast Track Drug Status
Other Accelerated Methods for Drug Approval
Pharmaceutical Regulatory Exclusivity
Pediatric Extensions
Biopharmaceutical Industry—Biosimilar (Biogeneric) Development and Exclusivity
Legislation
Aging Population
Mergers, Acquisitions, and Collaborations
Contributors To R&D Success
R&D Spending
The Role of Contract Research Organization
Sustainability in a Changing Pharmaceutical Industry

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

Introduction
Pfizer, Inc.
 Overview
 Financial Performance and Investments

Late Stage Pipeline

Merck & Co., Inc.

Overview

Financial Performance and Investments

Late Stage Pipeline

Novartis

Overview

Financial Performance and Investments

Late Stage Pipeline

Sanofi

Overview

Financial Performance and Investments

Late Stage Pipeline

Roche Ltd.

Overview

Financial Performance and Investments

Late Stage Pipeline

GlaxoSmithKline plc

Overview

Financial Performance and Investments

Late Stage Pipeline

AstraZeneca plc

Overview

Financial Performance and Investments

Late Stage Pipeline

Johnson & Johnson

Overview

Financial Performance and Investments

Late Stage Pipeline

Eli Lilly & Company

Overview

Financial Performance and Investments

Late Stage Pipeline

Abbott Laboratories

Overview

Financial Performance and Investments

Late Stage Pipeline

Bristol-Myers Squibb Company

Overview

Financial Performance and Investments

Late Stage Pipeline

Takeda Pharmaceutical Co., Ltd.

Overview

Financial Performance and Investments

Late Stage Pipeline

TEVA Pharmaceutical Industries, Ltd.

Overview

Financial Performance and Investments

Late Stage Pipeline

Amgen, Inc.

Overview

Financial Performance and Investments

Late Stage Pipeline

Boehringer Ingelheim GmbH

Overview

Financial Performance and Investments

Late Stage Pipeline

Bayer AG

Overview

Financial Performance and Investments

Late Stage Pipeline

Novo Nordis

Overview

Financial Performance and Investments

Late Stage Pipeline

Astellas

Overview

Financial Performance and Investments

Late Stage Pipeline

Daiichi Sankyo

Overview

Financial Performance and Investmen

Late Stage Pipeline

Otsuka

Overview

Financial Performance and Investments

Late Stage Pipeline

CHAPTER FIVE: COMPANIES OF INTEREST

Introduction

Merck KGaA

Late Stage Pipeline

Gilead Sciences

Late Stage Pipeline

Eisai

Late Stage Pipeline

Mylan

Pipeline

Baxter International

Pipeline

Servier, Les Laboratoires

Pipeline

Celgene Corporation

Late Stage Pipeline

Mitsubishi Tanabe

Late Stage Pipeline

Allergan

Late Stage Pipeline

Forest Laboratories

Late Stage Pipeline

CSL Limited

Late Stage Pipeline

UCB SA

Late Stage Pipeline

Dainippon Sumitomo Pharma, Co., Ltd.

Late Stage Pipeline

Shire

Late Stage Pipeline

Biogen Idec

Late Stage Pipeline

Watson

Pipeline

Hospira

Late Stage Pipeline

Lundbeck A/S

Late Stage Pipeline

Kyowa Kirin
Late Stage Pipeline
Warner Chilcott plc
Late Stage Pipeline
Menarini Group
Late Stage Pipeline
Valeant Pharmaceuticals
Late Stage Pipeline
Purdue Pharma
Late Stage Pipeline
Grifols SA
Late Stage Pipeline
Shionogi & Co., Ltd.
Late Stage Pipeline
Actelion
Late Stage Pipeline
Ono Pharmaceutical Co.
Late Stage Pipeline
Santen Pharmaceutical Co.
Late Stage Pipeline
Reckitt Benckiser
Late Stage Pipeline
Taisho Pharmaceutical Co.
Late Stage Pipeline

CHAPTER SIX: MARKET FORECAST

Overview
Company Analysis
Pipeline Snapshot: Top 20 Companies
Market Trends and Value
Evaluating Changes in 2011 Market Value
Market Forecast
The Traditional Biotechnology Market
Biotechnology Market Facts and Forecast

APPENDIX: LIST OF COMPANIES

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—based on late stage development projects evaluated

Figure 1-1: Global Pharmaceutical Market Forecast by Therapeutic Segment, 2016—Potential Impact from Late-Stage Development

CHAPTER TWO: INTRODUCTION

Table 2-1: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2009

Figure 2-1: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, and 2009

Table 2-2: Phases of Clinical Drug Development

Table 2-3: Components of a Clinical Trial

Figure 2-2: Biotechnology Approvals by Year Range (FDA)

CHAPTER THREE: ISSUES AND TRENDS

Table 3-1: International Population Trend Age 65+

Table 3-2: United States Population Trend Age 65+

Table 3-3: Recent Pharmaceutical Business Mergers and Acquisitions

Table 3-4: Pharmaceutical/Biopharmaceutical R&D Statistics

Table 3-5: Total Industry R&D Spending 2004-2010

CHAPTER FOUR: WORLDWIDE PHARMACEUTICAL INDUSTRY LEADERS

Table 4-1: Top Biopharmaceutical Companies, 1-20 by 2011 Sales

Table 4-2: Pfizer's Total Company Revenue and R&D Spending 2007-2011

Figure 4-1: Pfizer's Total Company Revenue and R&D Spending 2007-2011

Table 4-3: Pfizer's Late Stage Product Pipeline

Figure 4-2: Pfizer's Late Stage Product Pipeline by Therapeutic Area

Table 4-4: Merck's* Total Company Revenue and R&D Spending 2007-2011

Table 4-5: Merck's Late Stage Product Pipeline

Table 4-5 (continued): Merck's Late Stage Product Pipeline

Figure 4-4: Merck's Late Stage Product Pipeline by Therapeutic Area

Table 4-6: Novartis' Total Company Revenue and R&D Spending 2007-2011

Table 4-7: Novartis' Late Stage Product Pipeline

Figure 4-7: Novartis' Late Stage Product Pipeline by Therapeutic Area

Table 4-8: Sanofi's Total Company Revenue and R&D Spending 2007-2011

Table 4-9: Sanofi-Aventis' Late Stage Product Pipeline

Figure 4-8: Sanofi Aventis' Late Stage Product Pipeline by Therapeutic Area

Table 4-10: Roche's Total Company Revenue and R&D Spending 2007-2011

Table 4-11: Roche's Late Stage Product Pipeline

Figure 4-10: Roche's Late Stage Product Pipeline by Therapeutic Area

Table 4-12: GlaxoSmithKline's Total Company Revenue and R&D Spending
2007-2011

Table 4-13: GlaxoSmithKline's Late Stage Product Pipeline

Figure 4-12: GlaxoSmithKline's Late Stage Product Pipeline by Therapeutic Area

Table 4-14: AstraZeneca's Total Company Revenue and R&D Spending 2007-2011

Table 4-15: AstraZeneca's Late Stage Product Pipeline

Figure 4-14: AstraZeneca's Late Stage Product Pipeline by Therapeutic Area

Table 4-16: Johnson & Johnson's Total Company Revenue and R&D Spending
2007-2011

Table 4-17: Johnson & Johnson's Late Stage Product Pipeline

Table 4-18: Eli Lilly's Total Company Revenue and R&D Spending 2007-2011

Table 4-19: Eli Lilly's Late Stage Product Pipeline

Figure 4-18: Eli Lilly & Co.'s Late Stage Product Pipeline by Therapeutic Area

Table 4-20: Abbott's Total Company Revenue and R&D Spending 2007-2011

Table 4-21: Abbott's Late Stage Product Pipeline

Figure 4-20: Abbott's Late Stage Product Pipeline by Therapeutic Area

Table 4-22: Bristol-Myers Squibb's Total Company Revenue and R&D Spending
2007-2011

Table 4-23: Bristol-Myers Squibb's Late Stage Product Pipeline

Table 4-23: Bristol-Myers Squibb's Late Stage Product Pipeline

Figure 4-22: Bristol-Myers' Late Stage Product Pipeline by Therapeutic Area

Table 4-24: Takeda's Total Company Revenue* and R&D Spending 2007-2011

Table 4-25: Takeda Pharmaceutical's Late Stage Product Pipeline

Figure 4-24: Takeda Pharmaceutical's Late Stage Product Pipeline by Therapeutic
Area

Table 4-26: TEVA's Total Company Revenue and R&D Spending 2007-2011

Table 4-27: TEVA's Late Stage Product Pipeline

Figure 4-26: TEVA's Late Stage Product Pipeline by Therapeutic Area

Table 4-28: Amgen's Total Company Revenue and R&D Spending 2007-2011

Table 4-29: Amgen's Late Stage Product Pipeline

Figure 4-28: Amgen's Late Stage Product Pipeline by Therapeutic Area

Table 4-30: Boehringer Ingelheim's Total Company Revenue and R&D Spending
2007-2011

Table 4-31: Boehringer Ingelheim's Late Stage Product Pipeline

Figure 4-30: Boehringer Ingelheim's Late Stage Product Pipeline by Therapeutic Area

Table 4-32: Bayer's Total Company Revenue and R&D Spending 2007-2011

Table 4-33: Bayer's Late Stage Product Pipeline

Figure 4-32: Bayer's Late Stage Product Pipeline by Therapeutic Area

Table 4-34: Novo Nordisk's Total Company Revenue and R&D Spending 2007-2011

Table 4-35: Novo Nordisk's Late Stage Product Pipeline

Figure 4-34: Novo Nordisk's Late Stage Product Pipeline by Therapeutic Area

Table 4-36: Astellas' Total Company Revenue and R&D Spending 2007-2011

Table 4-37: Astellas' Late Stage Product Pipeline

Figure 4-36: Astellas' Late Stage Product Pipeline by Therapeutic Area

Table 4-38: Daiichi Sankyo's Total Company Revenue and R&D Spending 2007-2011

Table 4-39: Daiichi Sankyo's Late Stage Product Pipeline

Figure 4-38: Daiichi Sankyo's Late Stage Product Pipeline by Therapeutic Area

Table 4-40: Otsuka Holding's Total Company Revenue and R&D Spending 2007-2011

Table 4-41: Otsuka Pharmaceutical's Late Stage Product Pipeline

Figure 4-40: Otsuka Pharmaceutical's Late Stage Product Pipeline by Therapeutic Area

CHAPTER FIVE: COMPANIES OF INTEREST

Table 5-1: Top Biopharmaceutical Companies, 21-50 by 2011 Sales

Table 5-2: Merck KGaA's Late Stage Product Pipeline

Table 5-3: Gilead Sciences' Late Stage Product Pipeline

Table 5-4: Eisai's Late Stage Product Pipeline

Table 5-5: Celgene's Late Stage Product Pipeline

Table 5-6: Mitsubishi Tanabe's Late Stage Product Pipeline

Table 5-7: Allergan's Late Stage Product Pipeline

Table 5-8: Forest Laboratories' Late Stage Product Pipeline

Table 5-9: UCB Pharma's Late Stage Product Pipeline

Table 5-10: Dainippon Sumitomo's Late Stage Product Pipeline

Table 5-11: Shire's Late Stage Product Pipeline

Table 5-12: Biogen Idec's Late Stage Product Pipeline

Table 5-13: Hospira's Late Stage Product Pipeline

Table 5-14: Lundbeck's Late Stage Product Pipeline

Table 5-15: Kyowa Kirin's Late Stage Product Pipeline

Table 5-16: Menarini's Late Stage Product Pipeline

Table 5-17: Valeant's Late Stage Product Pipeline

Table 5-18: Shionogi's Late Stage Product Pipeline

Table 5-19: Actelion's Late Stage Product Pipeline

Table 5-20: Ono Pharmaceutical's Late Stage Product Pipeline

Table 5-21: Santen's Late Stage Product Pipeline

Table 5-22: Taisho's Late Stage Product Pipeline

CHAPTER SIX: MARKET FORECAST

Table 6-1: Top Biopharmaceutical Companies, 1-50 by 2011 Sales

Table 6-1 (Continued): Top Pharmaceutical/Biopharmaceutical Companies, 1-50 by 2011 Sales

Table 6-2: Company Pipelines by Total Late Stage Development Projects
(Top 20 Companies by Revenues)

Figure 6-1: Company Pipelines by Total Late Stage Development Projects (Top 20
Companies by Revenues)

Table 6-3: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010

Figure 6-2: Global Pharmaceutical Market Value by Therapeutic Segment, 2005-2010

Table 6-4: Global Pharmaceutical Market Value by Therapeutic Segment, 2010 vs.
2011

Figure 6-3: Global Pharmaceutical Market Value by Therapeutic Segment, 2010 vs.
2011

Table 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2016—based on late stage development projects evaluated

Figure 6-4: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2016—based on late stage development projects evaluated

Figure 6-5: Global Pharmaceutical Market Forecast by Therapeutic Segment,
2016—Potential Impact from Late-Stage Development

Figure 6-6: Global Pharmaceutical Market Forecast by, 2016—Potential Impact from
Late-Stage Development

Table 6-6: Top 5 Biotechnology Companies*, 2011 Sales

Table 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011 Revenues

Figure 6-7: Top 10 Biotechnology and Pharmaceutical Products, by 2011 Revenues

I would like to order

Product name: Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

Product link: <https://marketpublishers.com/r/PD05B68E42AEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD05B68E42AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

